Tempest Therapeutics price to sales ratio TPST

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 122×; Mar 2019
10-year median: 101×
10-year range: 59.7× to 198×
Peer median: 0.9×

Tempest Therapeutics' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Mar 2019, at 122×.

On the days it had one over the last ten years, its median was 101×, from 59.7× in Dec 2018 to 198× in Nov 2016.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2019	122×	69.9×	122×
2018	59.7×	59.7×	140×
2017	154×	76.5×	167×
2016	79.0×	72.3×	198×

Against its peers

Companies in Drug Manufacturers - General nearest Tempest Therapeutics' size, closest first, today.

Company	Price to sales ratio
TPSTTempest Therapeutics	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
Peer median	0.9×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Tempest Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.